Deerfield Invests $160 Million in MannKind Corporation
NEW YORK -- July 1, 2013
Deerfield Management Company has entered into an agreement with MannKind
Corporation (NASDAQ: MNKD) under which Mannkind may receive up to
$160,000,000. This financing is designed to support the regulatory process and
commercialization activities for Afrezza®, MannKind’s inhaled insulin product.
Deerfield funded $40,000,000 at closing and will fund three additional
$40,000,000 tranches as MannKind successfully completes its Phase III clinical
trial, repays its outstanding 3.75% convertible notes and receives FDA
approval for Afrezza®.
“We are pleased to be able to support MannKind’s innovative efforts to advance
the treatment of diabetes,” said James E. Flynn, General Partner at Deerfield.
“Diabetes remains one of the most prevalent, fastest growing and most
expensive diseases from a societal standpoint and efforts to fund more
effective and more widely adopted therapies are essential.”
Deerfield is a leading investment management firm, committed to advancing
healthcare through investment, information and philanthropy.
For more information, please visit www.deerfield.com
Deerfield Management Company
Karen Arnone, 212-922-1349
Press spacebar to pause and continue. Press esc to stop.